Animal Health Products
Taking advantage of our new pesticide discovery technology that we have fostered so far, we have developed (fuzapladib), an anti-pancreatitis drug for dogs.
We provide excellent products that the owners of companion animals and animal healthcare professionals depend on.
Fuzapladib Sodium Hydrate
In September 2018, we obtained manufacturing/marketing approval for this drug with the effect of “reduction of clinical signs associated with acute pancreatitis in dogs”.
Fuzapladib blocks activation of adhesion molecules (integrin) expressed on the inflammatory cell surface to prevent inflammatory cells from adhering to vascular endothelial cells and infiltrating tissue and to control exacerbation of pancreatitis.
This mode of action is different from that of conventional anti-inflammatory drugs including steroids and non-steroid anti-inflammatory drugs (NSAIDs).
No veterinary drugs with a similar action mechanism is available anywhere in the world, including Japan.
|IUPAC name||N-[2-(ethylsulfonylamino)-5-(trifluoromethyl)-3-pyridinyl]cyclohexanecarboxamide mono sodium salt monohydrate|
|Development code||IKV-741, IS-741, SH-741|
“Fuzapladib sodium hydrate” is an active pharmaceutical ingredient contained in “BRENDA™Z”.
ISK manufactures “fuzapladib sodium hydrate” and supplies it as an active pharmaceutical ingredient for animal use to Nippon Zenyaku Kogyo Co., Ltd.
ISK also obtained the manufacturing/marketing approval for “fuzapladib sodium hydrate” as the trade name, “BRENDA™”.
- Titanium Dioxide Products
- Functional Materials
- Environmental Products
- Heat Shield Materials
- Animal Health Products
- Organic Intermediates